GEN News Highlights: Mar 17, 2009

Aushon Acquires SearchLight Protein Array Business from Thermo Fisher Scientific

(Page 1 of 1)

    Aushon BioSystems procured Thermo Fisher Scientific’s SearchLight® Protein Array business and technology assets. With its microarray instrumentation and automation expertise, Aushon expects to be able to fully leverage SearchLight’s biomarker content and strengths in assay development.

    “SearchLight is a pioneer in the multiplex immunoassay market with one of the industry’s largest menus of disease-targeted biomarker panels,” according to Peter Honkanen, CEO of Aushon. “With the addition of the SearchLight technology platform and its products and services, we can now offer our clients a virtual one-stop shop for their biomarker research needs—from microarray printing and custom assay development to biomarker testing services in a CLIA-certified laboratory. As a result, our customers can expect increased reliability, improved performance, and the highest quality results.”

    SearchLight assets will be integrated into Aushon, but its offerings will continue to be marketed under the SearchLight brand. The combined business will operate under the name Aushon BioSystems, with headquarters in Billerica, MA. 

    Aushon’s portfolio of advanced products and services includes: Aushon 2470 Arrayer, a microarray printer for genomic and proteomic applications; versatile custom microarray printing; sample testing services that allows researchers to submit samples for quantitative analysis in custom biomarker arrays; custom arrays and assay development, which allows clients to select from a menu of more than 300 proteins to design an array consisting of 2 to 16 proteins per well; chemiluminescent and infrared assay kits including angiogenesis, cytokine, chemokine, and MMP arrays, each with detection antibody cocktails and reagents; and SearchLight Plus CCD imaging and analysis system.


Related content

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

FDA Performance

How much progress do you think FDA has made in reviewing drugs and bringing them to market faster?

Suggest a Poll